Smoking-related emphysema is a chronic inflammatory disease driven by the T H 17 subset of helper T cells through molecular mechanisms that remain obscure. Here we explored the role of the microRNA miR-22 in emphysema. We found that miR-22 was upregulated in lung myeloid dendritic cells (mDCs) of smokers with emphysema and antigen-presenting cells (APCs) of mice exposed to smoke or nanoparticulate carbon black (nCB) through a mechanism that involved the transcription factor NF-kB. Mice deficient in miR-22, but not wild-type mice, showed attenuated T H 17 responses and failed to develop emphysema after exposure to smoke or nCB. We further found that miR-22 controlled the activation of APCs and T H 17 responses through the activation of AP-1 transcription factor complexes and the histone deacetylase HDAC4. Thus, miR-22 is a critical regulator of both emphysema and T H 17 responses.
Pulmonary emphysema is a chronic inflammatory lung condition that, together with other smoking-related chronic obstructive pulmonary diseases, represents the third leading cause of death in the USA 1 . Emphysema is characterized by disruption of the lung matrix support that leads to the enlargement and destruction of the alveoli, which are the main gas-exchange units of the lungs, as well as enhanced collapsibility of conducting airways. These pathological changes, which are often accompanied by loss of the pulmonary microvasculature, combine to severely limit gas exchange and exercise tolerance. Emphysema is, furthermore, the most predictive clinical marker of lung cancer, which is the most deadly malignancy of industrialized societies 2 . Although tobacco smoking is its most important risk factor, emphysema is also seen in people who do not use tobacco but are chronically exposed to smoke derived from other sources 3 .
Susceptible smokers have activated cells of the T H 1 and T H 17 subsets of helper T cells in their lungs, and circulating elastin-specific autoimmune T cells have been cloned from the peripheral blood of smokers 4 . Elastin is the main structural protein of the lungs that tethers the airways open during exhalation, and accelerated loss of this matrix protein through the enhanced activity of elastases largely accounts for the dynamic airway collapse and lung hyperinflation that are characteristic of emphysema. Interferon-γ (IFN-γ) and interleukin 17A (IL-17A), the canonical T H 1 cytokine and T H 17 cytokine, respectively, promote the secretion of elastase from constitutive lung cells either directly or indirectly by promoting secretion of chemokines such as KC and macrophage inflammatory proteins that drive the recruitment of elastase-secreting neutrophils and macrophages to the lungs 5, 6 . However, the mechanism underlying the loss of peripheral tolerance to self antigens such as elastin and the induction of autoreactive T H 1 and T H 17 cells by cigarette smoke remains unclear.
Central to the development of such pathogenic T cells are lung CD1a + myeloid dendritic cells (mDCs) that assume a highly activated phenotype 6 . CD1a + mDCs from human smokers with emphysema and CD11c + antigen-presenting cells (APCs) from mice exposed chronically to cigarette smoke induce the T H 17 differentiation of syngeneic and allogeneic T cells through a mechanism that involves production of the cytokines IL-6 and osteopontin and inhibition of the transcription factor PPAR-γ 7, 8 . Indeed, smoke-exposed APCs are alone sufficient to promote the development of emphysema upon adoptive transfer to mice 7 . However, little is currently understood about how cigarette smoke initiates the activation of lung DCs and the initial smoke-activated molecular pathways that drive chronic inflammation and diseases such as emphysema.
MicroRNAs (miRNAs) represent a well-recognized layer of gene regulation that might critically influence immunological diseases such as emphysema. These are endogenous small noncoding RNAs, approximately 23 nucleotides in length, that post-transcriptionally regulate gene expression by binding to target sequences located within the 3′ untranslated regions of select mRNAs. They bind to their 3′ untranslated region targets in association with argonaute proteins within the cytoplasmic RNA-induced silencing complex, which leads to degradation of the mRNA or inhibition of its translation. Over 100 miRNAs are selectively expressed in cells of the mammalian immune system, many of which have been linked to either normal immune 1 1 8 6 VOLUME 16 NUMBER 11 NOVEMBER 2015 nature immunology A r t i c l e s responses or autoimmune disease 9 . Members of the extended let-7 family of miRNAs are pro-inflammatory and promote the development of allergic lung inflammation and disease that resembles allergic asthma 10 .
During a screen of selected miRNAs for immunoregulatory activity, we discovered a potential pro-inflammatory role for miR-22. We found that miR-22 was essential for the activation of DCs and the development of pulmonary emphysema resulting from the inhalation of cigarette smoke or nanoparticulate carbon black (nCB). Of the many targets of miR-22, the diverse immunological effects of miR-22 seemed to be driven through a single major target, the histone deacetylase HDAC4; decreased expression of HDAC4 led to a highly activated DC phenotype and robust T H 17 responses that drove the development of pulmonary emphysema. Selective inhibition of miR-22 in the airway thus represents a novel and potentially effective therapy for diverse pulmonary diseases and other inflammatory diseases.
RESULTS

Regulation of cigarette smoke-induced emphysema by miR-22
To establish a potential relationship between miR-22 and human emphysema, we determined how miR-22 expression is regulated in lung mDCs from smokers with and without lung disease. As assessed by reverse transcription followed by quantitative PCR (RT-qPCR), miR-22 expression was higher in CD1a + lung mDCs from subjects with emphysema than in those from control subjects without emphysema, and this was positively correlated with the severity of obstructive airway disease, as assessed by the forced expiratory volume in 1 s (Fig. 1a,b) . We further investigated the relationship between experimental emphysema in mice and miR-22 expression. Mice exposed to 4 months of cigarette smoke had significantly higher expression of miR-22 in their CD11c + lung APCs than did mice exposed to air alone (Fig. 1c) .
To determine if miR-22 is functionally linked to the pathogenesis of emphysema, we initially compared the ability of wild-type and Mir22 −/− mice to develop emphysema after 4 months of exposure to cigarette smoke. Wild-type mice exposed to smoke developed canonical features of emphysema, including enlargement of the alveolar spaces and increased total lung volume, accompanied by the accumulation of airway macrophages and neutrophils ( Fig. 1d-g ). In contrast, all emphysema-related parameters were either attenuated or abolished in Mir22 −/− mice ( Fig. 1d-g ). Quantification of lung helper T cell subsets after exposure to smoke showed specifically significantly fewer T H 17 cells in Mir22 −/− mouse lungs than in wild-type mouse lungs (Fig. 1h) . These data suggested that miR-22 was required for the development of cigarette smoke-induced experimental emphysema.
Requirement for APC miR-22 in nCB-induced emphysema Cigarette smoking leads to deposition in the lungs of nCB, an insoluble substance that accumulates specifically in and activates APCs that promote pathological T H 1 and T H 17 responses and emphysema 11 . To determine a potential role for miR-22 in nCB-dependent inflammation, we further compared the ability of wild-type and Mir22 −/− mice to develop emphysema after 1 month of exposure to nCB. We treated wild-type and Mir22 −/− mice with nCB intranasally twice weekly for 6 weeks in amounts that approximated smokers' lung nCB burdens (0.1 mg per gram of wet lung 11 ). At 4 weeks after the final instillation of nCB, Mir22 −/− mice exposed to nCB developed attenuated features of emphysema, including less enlargement of the alveolar spaces and reduced increases in total lung volume, relative to that of wild-type mice (Fig. 2a,b) . The recruitment of macrophages, neutrophils and T H 17 cells to the airways (Fig. 2c-e) and expression of the elastindegrading matrix metalloproteinases MMP9 and MMP2 in the airways (Supplementary Fig. 1a ) were also lower in Mir22 −/− mice than in wild-type mice, while Mir22 −/− mice and wild-type mice had similar numbers of lung IL-17A + γδ + T cells (Supplementary Fig. 1b) . We then immunized mice with ovalbumin and confirmed that miR-22 was selectively required for the antigen-specific development of T H 17 cells, not that of T H 1 cells or T H 2 cells, in vivo (Supplementary Fig. 2) .
Quantification of cytokine production after nCB challenge further showed less secretion of IL-6, KC, MCP-1 and MIP-1β from lung homogenates of Mir22 −/− mice than from those of wild-type mice ( Supplementary Fig. 3a-d npg from nCB-challenged mice ( Fig. 2a) and cultured the cells overnight ex vivo. Mir22 −/− APCs isolated after exposure to nCB secreted significantly less IL-1β, IL-6, KC, MCP-1 and MIP-1β than did their wild-type counterparts (Fig. 2f,g and Supplementary Fig. 3e-g ). Mir22 −/− APCs exposed to nCB were also less efficient than their wild-type counterparts at driving the secretion of IL-17A from wildtype T cells in vitro (Fig. 2h) . Fig. 2i-k) . Furthermore, adoptive transfer of CD11c + lung APCs isolated from cigarette smoke-exposed wild-type mice induced emphysema, macrophage infiltration and lung T H 17 cell development in both naive wild-type recipient mice and naive Mir22 −/− recipient mice ( Supplementary Fig. 4 ). Together these findings confirmed that APC-specific miR-22 was necessary and sufficient for the induction of lung T H 17 responses and emphysema.
Transcription factor NF-kB regulates miR-22 expression
The expression of miR-22 in human CD1a + mDCs and monocytederived DCs from subjects without emphysema was enhanced after exposure to nCB ex vivo (Fig. 3a,b) . We observed similarly enhanced miR-22 expression in mouse bone marrow-derived DCs (BMDCs) treated with a variety of activating stimuli, including various Toll-like receptor ligands and agonistic ligation of the costimulatory receptor CD40, in addition to nCB (Fig. 3c) . The expression of miRNAs typically correlates with that of the host genes from which they derive 13 . The miR-22 primary RNA transcript (pri-miRNA) host gene transcription unit (Mir22hg) was also induced by nCB and several, but not all, Toll-like receptor ligands (including lipopolysaccharide (LPS), the synthetic lipoprotein FSL-1 (Pam 2 CGDPKHPKSF), the synthetic RNA duplex poly(I:C), the lipopeptide Pam 3 CSK 4 , and lipoteichoic acid) in mouse BMDCs (Fig. 3d) . Ligation of CD40 with antibody to CD40 (anti-CD40) conspicuously failed to induce Mir22hg expression (Fig. 3d) , which suggested that the increase in mature miR-22 due to this form of stimulation might have been the result of enhanced processing of extant Mir22hg transcripts or diminished consumption of miR-22. To understand how the Mir22hg is regulated in APCs, we cloned the 2.3-kilobase promoter region upstream of the Mir22hg transcriptional start site into a reporter plasmid encoding enhanced green fluorescent protein (eGFP) and generated multiple deletion mutants, which we transfected into RAW264.7 mouse macrophages. Both basal promoter activity and promoter activity stimulated with LPS (1 ng/ml) progressively decreased as the promoter was shortened (Fig. 3e) , which suggested that all regions of this promoter domain contained elements that regulated Mir22hg expression.
Through the use of TFSearch, a server for the prediction of transcription factor-binding sites, we found six predicted potential consensus sequences for the transcription factor AP-1 and one predicted consensus sequence for the transcription factor NF-κB within the 2.3-kilobase promoter region of Mir22hg (Fig. 3e) . To determine if Mir22hg promoter activity is regulated by AP-1 and NF-κB, we treated RAW264.7 cells carrying a 2.3-kilobase Mir22hg promoter A r t i c l e s plasmid either with an inhibitor of the c-Jun (AP-1 subunit) kinase Jnk (SP600125) to block AP-1 activity or with the proteasome inhibitor MG132 to block NF-κB activity. MG132 significantly inhibited eGFP expression with and without LPS stimulation (Fig. 3f) . Moreover, chromatin-immunoprecipitation assays revealed more binding of the NF-κB subunit RelA (p65) but less binding of c-Jun within the Mir22hg promoter region in LPS-treated BMDCs than in unstimulated BMDCs (Fig. 3g) . MG132 further impaired the expression of both Mir22hg and miR-22 in nCB-treated BMDCs (Fig. 3h,i) . Together these observations indicated that NF-κB enhanced the activity of the Mir22hg promoter in APCs, which suggested that miR-22 was an NF-κB-responsive miRNA in these cells.
To further understand the role of NF-κB and related transcription factors in regulating miR-22 expression, we assessed the abundance of miR-22 in PPAR-γ-deficient lung APCs. PPAR-γ is an inhibitor of NF-κB activity and the development of emphysema 14, 15 . Consistent with those observations, miR-22 expression was upregulated in PPAR-γ-deficient lung APCs compared with that of PPAR-γ-sufficient control APCs (Supplementary Fig. 5a ). Moreover, intranasal treatment of smoke-exposed mice with the PPAR-γ agonist ciglitazone reduced the expression of miR-22 in lung APCs (Supplementary Fig. 5b ). Together these observations indicated that PPAR-γ inhibited miR-22 expression in APCs, probably through the inhibition of NF-κB activity. These findings provide insight into the transcriptional mechanism underlying the enhanced miR-22 expression seen in APCs derived from subjects with emphysema.
Requirement for miR-22 in APC activation
To further investigate the immunological importance of miR-22 in APCs, we assessed the expression profiles of mRNAs encoding proinflammatory molecules in CD11c + APCs isolated from the lungs of wild-type and Mir22 −/− mice that were exposed to nCB. Mir22 −/− lung APCs had lower expression of mRNA encoding c-Jun (a subunit of AP-1), the co-stimulatory molecules CD86 and CD40, the chemokine CCL8, and the metalloproteases MMP13 and MMP14 than did their wild-type counterparts ( Fig. 4a and Supplementary Fig. 6 ). After treatment overnight with LPS or agonistic antibody to CD40, Mir22 −/− BMDCs further showed significantly lower surface expression of CD86 and CD40 and less secretion of IL-6 than did their wild-type counterparts ( Fig. 4b-d) . In vitro, nCB also induced less secretion of IL-6 from Mir22 −/− BMDCs than from wild-type BMDCs (Fig. 4e) . nCB-treated miR-22-deficient BMDCs induced less secretion of IL-17A from co-cultured naive wild-type T cells than did nCB-treated miR-22-sufficient APCs (Supplementary Fig. 7) . However, this defect in IL-17A secretion was abrogated by the addition of IL-6 to the culture conditions (Supplementary Fig. 7) . Conversely, transfection of miR-22 mimics into unstimulated mouse BMDCs was alone sufficient to induce the expression of Il1b, Il6, Il23a and Cd86 mRNA (Fig. 4f) and also enhanced the secretion of IL-6 dependent on LPS or agonistic antibody to CD40 (Fig. 4g) . In a dose-dependent manner, miR-22 was similarly required for robust LPS-dependent secretion of IL-6 from human monocyte-derived DCs (Fig. 4h) . Thus, miR-22 drove the production of cytokines such as IL-6 and co-stimulatory molecules that are required for robust T H 17 responses.
Impaired AP-1 activity in Mir22 −/− APCs Ligation of CD40 triggers APC maturation mainly through NF-κB and AP-1, two transcription factors that promote the expression of inflammatory cytokines and co-stimulatory molecules [16] [17] [18] [19] . To determine if miR-22 regulates the activation of NF-κB and AP-1 in APCs, we treated wild-type and Mir22 −/− mouse BMDCs with agonistic antibody to CD40. As assessed by immunoblot analysis, there was no substantial difference between wild-type cells and Mir22 −/− cells in their production of the NF-κB p50 or p52 fragments from their precursors p105 (NF-κB1) or p100 (NF-κB2) (Fig. 5a) . We further assessed the phosphorylation status of major signaling proteins in BMDCs from wild-type and Mir22 −/− mice by reverse-phase protein array. Phosphorylation of c-Jun increased in wild-type BMDCs, but not in Mir22 −/− BMDCs, after treatment with anti-CD40, while phosphorylation of the upstream mitogen-activated protein kinases MEK1, p38α, Erk1/2 and Jnk showed similar patterns in wild-type and Mir22 −/− BMDCs (Fig. 5b) , which suggested that the lack of c-Jun phosphorylation in Mir22 −/− BMDCs was not due to disruption of upstream kinase pathways. We next assessed the expression of c-Jun in wild-type and Mir22 −/− BMDCs by immunoblot analysis. Expression of c-Jun increased in wild-type BMDCs but decreased in Mir22 −/− BMDCs after treatment with anti-CD40 (Fig. 5c) . After 24 h of stimulation, there was less c-Jun in Mir22 −/− BMDCs than in wild-type BMDCs (Fig. 5c) , which suggested that miR-22 might be an important regulator of c-Jun expression in APCs.
To address this further, we transfected an AP-1 reporter plasmid (containing sequence encoding GFP controlled by a promoter element specific to the gene encoding AP- 
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with anti-CD40 (Fig. 5d) . Collectively, these data confirmed that miR-22 promoted the transcriptional activity of AP-1 in APCs.
miR-22 targets HDAC4 in APCs miR-22 putatively regulates several hundred genes (as suggested by the TargetScanHuman website for the prediction of miRNA targets).
To begin to determine the critical miR-22-dependent genes that underlie T H 17 responses and emphysema, we again compared the gene-expression profiles of CD11c + APCs isolated from the lungs of wild-type and Mir22 −/− mouse exposed to nCB, focusing on putative miR-22 target genes that were downregulated in wild-type APCs but downregulated less in Mir22 −/− APCs (Fig. 6a) . To screen for functional relevance to APC activation, we then used small interfering RNA (siRNA) to knock down in Mir22 −/− BMDCs the genes (Ogn, Hdac4 and Acvr2b) that were most differentially expressed in lung APCs from nCB-exposed Mir22 −/− mice relative to their expression in those from nCB-exposed wild-type mice. Of these putative targets, the impairment in IL-6 secretion shown above for Mir22 −/− BMDCs upon stimulation with anti-CD40 (Fig. 4c) was partially restored only by knockdown of Hdac4 (Fig. 6b) , which has been shown to be a true miR-22 target [20] [21] [22] . To confirm that miR-22 regulated HDAC4 expression in APCs, we first showed that neutralization of miR-22 in naive mouse BMDCs with an antisense locked nucleic acid (LNA) enhanced the expression of both Hdac4 mRNA and HDAC4 protein (Fig. 6c,d) . Moreover, after stimulation of cells with anti-CD40, HDAC4 expression decreased in wild-type BMDCs but increased in Mir22 −/− BMDCs (Fig. 6e) . Finally, knockdown of Hdac4 by siRNA in Mir22 −/− BMDCs or BMDCs transfected with LNA targeting miR-22 restored their ability to induce IL-17A secretion from co-cultured naive wild-type T cells after stimulation with nCB ( Fig. 6f,g) . Collectively, these studies confirmed that Hdac4 was a major target of miR-22 in APCs and suggested the existence of an obligatory regulatory pathway in which activated APCs enhance the expression of miR-22 that then inhibits HDAC4 expression to promote T H 17 responses.
HDAC4 inhibits APC activation and emphysema development HDAC4 is a class II histone deacetylase and is therefore a potential epigenetic regulator 23, 24 . The deacetylation of histones in gene npg promoter regions results in chromosomal condensation, which diminishes the potential for genes in these regions to be transcriptionally activated. Published studies have shown that loss of HDAC4 in myeloid cells results in exacerbated inflammation in mice fed a high-fat diet, which would suggest an anti-inflammatory role for APC-specific HDAC4 in some contexts 25 . To establish a potential link between HDAC4 and emphysema, we first quantified the expression of HDAC4 mRNA or Hdac4 mRNA in human monocyte-derived DCs and mouse BMDCs, respectively, with or without nCB challenge. The expression of mRNA encoding HDAC4 was significantly downregulated after nCB challenge of both the monocyte-derived DCs and the BMDCs (Fig. 7a,b) . We then created mice with conditional deletion of Hdac4 in APCs by crossing mice with a loxP-flanked Hdac4 allele (Hdac4 fl ) with mice expressing CD11c-Cre (to generate 'Hdac4 CD11c ' mice). HDAC4-deficient BMDCs from Hdac4 CD11c mice secreted more IL-6 in both the naive state and activated state in response to stimulation with LPS or anti-CD40 than did BMDCs generated from Hdac4 fl (control) mice (Fig. 7c,d ). Upon stimulation with nCB, HDAC4-deficient BMDCs and splenic DCs induced even more IL-17A production from cocultured naive T cells than did their HDAC4-sufficient counterparts (Fig. 7e,f) . The 'hyper-induction' of IL-17A by HDAC4-deficient cells was partially or totally offset by the addition of a neutralizing antibody to IL-6 to the cultures (Fig. 7e,f) . HDAC4 has been shown to suppress c-Jun expression 26, 27 . Indeed, we found higher c-Jun expression in Hdac4 CD11c BMDCs than in Hdac4 fl BMDCs with or without stimulation with anti-CD40 (Fig. 7g) . After exposure to nCB, Hdac4 CD11c mice developed exacerbation of multiple parameters of emphysema relative to the disease of Hdac4 fl mice, including exaggerated alveolar enlargement, airway volume and infiltration of macrophages and neutrophils into the airways (Fig. 7h-k) . Together these observations indicated that HDAC4 was a potent suppressor of nCB-dependent inflammation and that miR-22-dependent suppression of HDAC4 was required for full development of the emphysema phenotype.
Reversal of mouse emphysema by anti-miR-22
The studies reported above suggested that either neutralization of miR-22 or enhanced expression of HDAC4 in vivo would attenuate the development of emphysema. As it is not technically possible to enhance the activity of constitutive HDAC4 in vivo, we instead neutralized miR-22 in vivo by delivering an LNA targeting miR-22 intranasally into emphysematous mice that were previously exposed to nCB. We exposed 2-month-old wild-type mice to nCB or PBS for 1 month and allowed them to 'rest' for another month. At the age of 4 months, mice previously exposed to nCB developed severe emphysema, as determined by quantification of lung volume through the use of micro-computerized tomography (micro-CT) (Fig. 8a) . nCB-exposed mice then continued to develop severe emphysema after 1 month of treatment with a control LNA with a scrambled sequence, whereas nCB-exposed mice treated with the LNA targeting miR-22 showed evidence of resolution of emphysema, as determined by lung volume and lung histology (mouse age, 5 months; Fig. 8a,b) . 
A r t i c l e s
We continued to treat the two mouse groups similarly for 2 additional months and found that after a total of 3 months of treatment with LNA, mice treated with the control LNA showed continued disease progression, whereas mice treated with the LNA targeting miR-22 had significantly lower lung volumes (mouse age, 7 months; Fig. 8a) . At 3 months after the cessation of LNA treatment, emphysema returned fully in the mice treated with the LNA targeting miR-22 (mouse age, 10 months; Fig. 8a,b) . After 1 month of treatment with the LNA targeting miR-22 (mouse age, 5 months), miR-22 was essentially undetectable in mouse lungs (Supplementary Fig. 8a ). These mice further showed less infiltration of macrophages and neutrophils into the lungs, fewer T H 17 cells from whole lung, and diminished secretion of IL-6 and IL-17A into lung homogenates than did mice treated with the control LNA (Fig. 8c-e and Supplementary Fig. 8b,c) . We also found higher expression of Hdac4 mRNA and, conversely, lower expression of Il6 and Cd40 mRNA in CD11c + lung APCs from mice treated with LNA targeting miR-22 than in those from mice treated with the control LNA ( Supplementary  Fig. 8d-f) . Mice previously treated with LNA targeting miR-22 still showed less infiltration of macrophages and neutrophils into the lungs than did mice previously treated with the control LNA, but they had numbers of T H 17 cells from whole lung similar to those of mice previously treated with the control LNA (Fig. 8c-e) . Thus, prolonged treatment with an LNA that inhibited miR-22 reversed fully established emphysema and the activation of lung APCs.
DISCUSSION
We have identified miR-22 as a critical regulator of the activation of DCs in response to cigarette smoke and smoke-derived nCB that underwent phagocytosis by diverse lung APCs. Lung DCs activated with nCB secreted IL-6 and expressed discrete co-stimulatory molecules that are required for the differentiation and effector function of T H 17 cells and that we found were controlled through miR-22. Although miR-22 probably influences many genes encoding products related to immunity, much of the pro-inflammatory activity of miR-22 was mediated through the post-translational suppression of HDAC4. Together our findings expand the understanding of miRNAs in immunity and reveal a new strategy with which treat emphysema and potentially other T H 17 cell-related pathological conditions. miR-22 has been linked to control of the cardiac response to acute stress 28, 29 and regulation of the differentiation of mesenchymal stem cells 30 , but this is the first demonstration to our knowledge of a critical immunological function for this miRNA. Like many other miRNAs, miR-22 has also been linked to cancer phenotypes. In some contexts, miR-22 is viewed as a tumor suppressor 31 , with various human tumors showing repression of miR-22 expression relative to its expression in surrounding normal tissue 32 . In contrast, overexpression of miR-22 induces myelodysplastic syndrome and bone marrow malignancies in mice 33 , which would suggest that this miRNA might, under other circumstances, act as a tumor promoter. Over the approximately 5 years that we have monitored our miR-22-deficient mouse colony, we have not noticed early mortality or the development of tumors of any kind. Moreover, we have not noticed unusual mortality or tumors in wild-type mice treated with LNA targeting miR-22. Thus, whereas manipulation of any miRNA or other genetic element carries a theoretical risk of cellular transformation, our experience does not indicate that loss of miR-22 in vivo is alone sufficient to promote cancer.
In contrast to miR-22, HDACs have been linked to the pathogenesis of emphysema. HDAC activity in lung biopsies and lung macrophages of subjects with emphysema who smoke was found to be suppressed, relative to its activity in such samples from non-smokers, in a manner positively correlated with disease severity 2 . Those observations were linked to HDAC2, HDAC5 and HDAC8, and subsequent studies have suggested that less deacetylation of the glucocorticoid receptor npg by HDAC2 in emphysema antagonizes the ability of corticosteroids to inhibit the pro-inflammatory potential of NF-κB 9 . Corticosteroids are notoriously ineffective in chronic obstructive pulmonary disease and/or emphysema 34 ; thus, this mechanism suggests that interventions that increase activity of HDAC2 might enhance the effectiveness of corticosteroids. Subsequent study of HDAC inhibitors in rodents and in vitro has further suggested an anti-inflammatory role for HDACs in emphysema 35 . However, the broad-spectrum nature of these inhibitors precludes delineation of the most relevant antiinflammatory HDACs. Independent lines of evidence have, however, established clear links to immunological regulation for HDAC4, which functions as a co-repressor of multiple immunologically related transcription factors, including c-Jun, NF-κB and Bcl-6, and regulates IL-5 expresion 26, 27, [36] [37] [38] . HDAC4 also promotes activation of STAT6 and expression of arginase-1 that is required for the differentiation of myeloid DCs 39 . Our studies have now shown that HDAC4 was essential for suppressing T H 17 responses and nCB-dependent emphysema in mice. Together with our analyses of miR-22, our findings suggest the existence of a pro-inflammatory regulatory loop in which noxious stimuli such as carbon black enhance the expression miR-22 that then suppresses HDAC4 sufficiently to promote the differentiation of T H 17 cell-promoting DCs. We have emphasized the role of HDAC4 in controlling DC-derived IL-6, but the expression of CD40, CD86 and c-Jun was also impaired in the context of less miR-22 and enhanced HDAC4 activity. As all of these factors are required for its development, our findings explain the requirement for a pleiotropic suppressive factor such as HDAC4 in the regulation of the highly complex T H 17 response [40] [41] [42] [43] .
Our findings do not rule out the possibly of a role for HDAC2 and other HDACs in the regulation of inflammation in emphysema. Nonetheless, our mechanistic delineation of the pro-inflammatory role of miR-22 in emphysema has revealed that HDAC4 specifically regulated smoking-related lung inflammation and T H 17 responses and might account for much of the HDAC-related anti-inflammatory activity that has been reported on the basis of studies with inhibitors. IL-17A and T H 17 cells have also been linked to many chronic diseases other than emphysema that are related to dysregulation of the immune system, including asthma 44 , inflammatory bowel disease 45, 46 , rheumatoid arthritis 47 and others. Interventions that inhibit miR-22 or enhance HDAC4 activity might thus be broadly useful in the therapy of many human diseases caused by chronic inflammation.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE72734. 
